1. Aida Drljevic, Dom Zdravlja Tuzla,
Federation of Bosnia and Herzegovina
, Bosnia and Herzegovina
2. Amra Nadarevic Vodencarevic, JZNU Dom zdravlja Tuzla,
Federation of Bosnia and Herzegovina
, Bosnia and Herzegovina
3. Svjetlana Terzic, UKC TUZLA,
Federation of Bosnia and Herzegovina
, Bosnia and Herzegovina
INTRODUCTION:
Glaucoma is a common sight-threatening condition that is primarily treated by lowering intraocular pressure (IOP). The main first-line treatment strategy for glaucoma is to reduce IOP by topical ocular hypotensive medications, but many patients especially with secundary glaucoma require multiple medications for adequate IOP control.
OBJECTIVE:
To evaluate the efficacy of topical fixed therapy of brinzolamid 1%-brimonidin 0,2% for secondary glaucoma.
PATIENTS AND METHODS:
The study design was retrospective. Ten (10) patients diagnosed with secondary glaucoma were enrolled from Health Center Tuzla, Department of Ophthalmology, from March 2016 to April 2017. The IOP change between the baseline visit before switch to the brinzolamid1%-brimonidin0,2% fixed combination occurred, and the first follow-up control after the switch, served as an indicator of compliance.
RESULTS:
The most common reason for high IOP was neovascular glaucoma. Neovascular glaucoma was observed in three (3) patients, followed by secondary glaucoma after surgery in two (2) patients and traumatic glaucoma in two (2) patients. We observed also in one (1) patient uveitic glaucomas. The IOP decreased on average from 49.7 ± 8.78 mmHg to 25.2 ± 5.07 mmHg There were no common systemic adverse effects in nine (9) patients. Only one patient reported that since he used drugs had oral dryness.
CONCLUSION:
Monotherapy didnt provide sufficient IOP reduction in these patients, thereby necessitating the use of multiple IOP-lowering medications. Multi drug regimens may be complex. We conclude that simbriza is effective in the treatment of secundary glaucoma, although there is a always a need to be aware of potential complication of secundary glaucoma. Currently in Bosnia and Herzegovina Simbrinza is the only fixed combination without a β-blocker. Longer-term experience will determine if additional adverse effects occur or if efficacy is maintained over longer periods.
Кључне речи :
Тематска област:
Глауком
Датум:
28.04.2017.
Други конгрес офталмолога Републике Српске са међународним учешћем
